The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

摘要: Pathogen reduction technologies (PRTs) have been developed to further reduce the current very low risks of acquiring transfusion-transmitted infections and promptly respond emerging infectious threats. An entire portfolio PRTs suitable for all blood components is not available, but field steadily progressing. While plasma used many years, platelets, red cells (RBC) whole (WB) were more slowly, due difficulties in preserving cell functions during storage. Two commercial platelet use ultra violet (UV) A UVB light presence amotosalen or riboflavin inactivate pathogens' nucleic acids, while a third experimental PRT uses UVC only. WB RBC tested clinical trials with storage limited 21 35 days, unacceptably high lesion beyond these time limits. This review summarizes pre-clinical investigations selected outcomes from using above PRTs. Further studies are warranted decrease lesions after treatment test different medical surgical conditions. Affordability remains major administrative obstacle use, particularly so geographical regions higher transfusion-transmissible infections.